Mental health · Atlanta area, GA
Mental health studies in Atlanta area, GA
81 recruiting studies have a site in the Atlanta area. This page includes nearby cities such as Decatur, Marietta, Sandy Springs, Alpharetta.
81 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- Atlanta, GA + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Alkermes, Inc.
- Location
- Decatur, GA + 17 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Sandy Springs, GA + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Atlanta, GA + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Atlanta, GA + 12 other US sites
- Eligibility basics
- Ages 13–17
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Atlanta, GA + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Decatur, GA + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Vanda Pharmaceuticals
- Location
- Atlanta, GA + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Atlanta, GA + 33 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Augusta, GA + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Neurocrine Biosciences
- Location
- Atlanta, GA + 10 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
- Location
- Atlanta, GA + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Atlanta, GA + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc.
- Location
- Atlanta, GA + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Atlanta, GA + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Atlanta, GA + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Atlanta, GA + 24 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Atlanta, GA + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Decatur, GA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Atlanta, GA + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Atlanta, GA + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Atlanta, GA + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC
- Location
- Marietta, GA + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Snellville, GA + 24 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.